Navigation Links
Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
Date:9/24/2007

EAST SETAUKET, N.Y., Sept. 24 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) today announced the trading of its common shares on the Over-The-Counter Bulletin Board under the Symbol LIXT.

Commenting on this important milestone, President and CEO John S. Kovach, M.D. stated, "We believe that being a publicly traded company will enable us to pursue funding opportunities that were not available to us as a private company. Having access to the capital markets is important at this stage of Lixte's development. Over the coming months our strategy is to continue with our research under a Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH), while at the same time exploring other cancer research opportunities that Lixte is developing independently."

About Lixte Biotechnology Holdings, Inc.:

Lixte Biotechnology Holdings, Inc. (Lixte) is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, the company develops new chemotherapy drugs targeting molecular abnormalities of common human cancers. Over the past year, based on the discovery of a new biomarker for brain cancers by collaborators at NIH, the company is developing new drugs for the treatment of glioblastoma multiforme (GBM), the most common and most aggressive type of primary brain cancer in adults and, to a much lesser extent, in children.

GBM occurs annually in 20,000 to 25,000 adults in the United States and in a comparable number of individuals in Europe. At present, there is no curative treatment known for this disease. Standard treatment involves surgery, radiation and the use of one or more chemotherapeutic agents at the time of initial treatment. At relapse, which occurs in essentially all patients, the present standard treatment is a drug, Temozolomide, that is associated with a modest increase
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Olympics of biotechnology has international flavor
2. Making Wisconsin the biotechnology leader
3. Let the olympics of biotechnology in the Midwest begin!
4. The mushrooming of biotechnology in the U.S.
5. 42 days until the 2006 Olympics of Biotechnology in Chicago
6. Third coast of biotechnology makes strong showing at VC conference
7. State wants to encourage industrial biotechnology
8. The Scientist magazine names Madison "hotspot" for biotechnology
9. First graduates boon to Wisconsin biotechnology
10. Americas Third Coast nurtures biotechnology
11. Florida: Investing Heavily in Biotechnology - Governor uses state funds to attract large biotech companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014 Continental Clinical Solutions, ... into clinical trials at its mid-Atlantic late-phase research ... was created with the idea of closing patient ... role in medical advances," said Continental's CEO, ... to the immortal cell line of Henrietta Lacks, ...
(Date:11/24/2014)... 24, 2014 The new video, ... METTLER TOLEDO demonstrates how to reduce the number ... and sample panel design can be complicated, requiring ... protect against corrosion and deposition. Dedicated single and ... amount of panel space. Additionally, installing and maintaining ...
(Date:11/24/2014)... Senior Vice President, General Manager ... skills, business acumen Elsevier , a ... and services, congratulates Diane Bartoli , Senior Vice ... Elsevier Clinical Solutions, for being recognized in the 13 ... issue of Profiles in Diversity Journal ® ...
(Date:11/22/2014)... Two new educational webinars hosted by DrugDev ... research and how the pharmaceutical industry can make life easier ... Where Does the ALS Money Go? , Featuring guest speaker ... 1:30pm ET, Register to attend , This webinar ... Julianne Dorn Professor of Neurology at Massachusetts General Hospital at ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3New Video Shows How to Simplify Cycle Chemistry Sample Panels to Save Time and Costs 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2
... 22 Maven Biotechnologies, LLC,an early stage ... system, today announced that the company will,deliver ... in San Diego,California. Jeffrey C. Travis, Ph.D., ... November 1, 2007 at 3:30 PM. ...
... Called Upon to Help One Deserving Facility Win Needed Medical ... Its Favorite ,Clinical Contender, MALVERN, Pa., Oct. 22 ... of the clinical challenges in hospitals,across the country to millions ... technology - a magnetic resonance imaging,(MRI) system - are being ...
... PCOP ), an innovator in the discovery and ... Leslie J. Browne,President and Chief Executive Officer, will deliver ... 9th Annual Healthcare,Conference. The conference will be held November ... in New York City. Dr. Browne,s presentation will ...
Cached Biology Technology:Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference 2American M.R.I.-DOL: Small Hospitals To Turn The Camera On Themselves In Unique National Contest 2American M.R.I.-DOL: Small Hospitals To Turn The Camera On Themselves In Unique National Contest 3Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 4
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/12/2014)... PALM BEACH GARDENS, Fla. , Nov. 12, 2014 ... management solutions, announced today that its U.are.U ® ... upscale retail bakery chain in Central Mexico ... solution in June 2014 to eliminate payroll issues caused ... Prior to installing the U.are.U fingerprint readers, Montparnasse ...
(Date:11/7/2014)... -- Leading Biometric companies aim to provide consumers ... transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ), Microsoft Corporation ... EBAY ) and MasterCard Inc. (NYSE: MA) NXT-ID, ... authentication company focused on the growing mobile commerce is pleased ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... scientists studying genetic pathways that are mutated in many ... of congenital heart disease including hypertrophic cardiomyopathy (HCM), ... leading cause of sudden death in children and young ... successfully treated HCM in the lab. In ...
... of California, Davis, will present these findings at ... the Advancement of Science in Washington, D.C., on ... from the Transportation Sector, Presenter: Christopher Yang, UC ... Friday, Feb. 18, 2 p.m., Location: 206 Washington ...
... biologist Graham Walker leads a research group focused on ... excitement of his research lab: doctoral and graduate students ... new research questions in science education and brainstorm ways ... his experiences running a science education research group and ...
Cached Biology News:Cancer-related pathways reveal potential treatment target for congenital heart disease 2Cancer-related pathways reveal potential treatment target for congenital heart disease 3AAAS news briefs from UC Davis 2AAAS news briefs from UC Davis 3AAAS news briefs from UC Davis 4AAAS news briefs from UC Davis 5Plenary speech by HHMI professor highlights efforts of scientist-educators 2Plenary speech by HHMI professor highlights efforts of scientist-educators 3
RAT ANTI RAT RT1Au (CLASS I POLYMORPHIC) Immunogen: AO lymphoid cells...
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
MOUSE ANTI SIMIAN VIRUS 5:FITC Immunogen: Simian virus 5...
Collected from normal, healthy animals in carefully maintained standing herds of US orgin. Pricing: $45/unit for 1 - 10 units...
Biology Products: